SEC Contract Filing

Filing Date: 2018-05-04

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>alny-ex101_216.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alny-ex101_216.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">EXHIBIT 10.1</p>
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">Execution Copy</p>
<p style="text-align:right;Background-color:#auto;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">Amendment Agreement</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">AMENDMENT No. 2 TO THE COLLABORATION AGREEMENT</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS AMENDMENT NO. 2 TO THE COLLABORATION AGREEMENT (this &#8220;<font style="font-weight:bold;">Collaboration Amendment</font>&#8221; or this &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;), entered into as of January 6, 2018 (the &#8220;<font style="font-weight:bold;">Execution Date</font>&#8221;), is entered into by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (&#8220;<font style="font-weight:bold;">Alnylam</font>&#8221;) and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (&#8220;<font style="font-weight:bold;">Genzyme</font>&#8221;).</p>
<p style="Background-color:#auto;text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">RECITALS:</p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Parties entered into that certain Master Collaboration Agreement dated as of January 11, 2014 (the &#8220;</font>Original Collaboration Agreement<font style="font-weight:normal;">&#8221;), as amended by Amendment No. 1 to the Master Collaboration Agreement dated July 1, 2015 (&#8220;</font>Amendment No. 1<font style="font-weight:normal;">&#8221;) (the Original Collaboration Agreement, together with Amendment No. 1 and this Agreement, the &#8220;</font>Master Agreement<font style="font-weight:normal;">&#8221;) pursuant to which, among other things, Alnylam granted Genzyme the exclusive right to Develop and Commercialize ALN-TTR02, ALN-TTRsc, ALN-TTRsc02 (as a back-up to ALN-TTRsc) and ALN-AT3 on a regional basis outside the United States, Canada and western Europe and the further right to co-Develop and co-Commercialize ALN-TTRsc, ALN-TTRsc02 (as a back-up to ALN-TTRsc) and ALN-AT3 with Alnylam in the United States, Canada and western Europe, in each case on the terms and conditions set forth in the Master Agreement and the License Terms attached to the Master Agreement as </font><font style="text-decoration:underline;font-weight:normal;">Appendix A</font><font style="font-weight:normal;"> (Regional License Terms),</font> <font style="text-decoration:underline;font-weight:normal;">Appendix B</font> <font style="font-weight:normal;">(Global License Terms) and</font> <font style="text-decoration:underline;font-weight:normal;">Appendix C</font><font style="font-weight:normal;"> (Co-Co License Terms) (the Master Agreement, together with the License Terms attached thereto, the &#8220;</font>Collaboration Agreement<font style="font-weight:normal;">&#8221;) (capitalized terms used, but not defined, herein shall have the definition provided in the Collaboration Agreement); </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Parties desire to amend their respective rights and obligations with respect to certain matters that are the subject of the Collaboration Agreement; </font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, the Parties have agreed to revised terms and conditions pursuant to which Alnylam will pursue the further Development and Commercialization of ALN-TTR02, ALN-TTRsc and ALN-TTRsc02 and any Back-Up Products (as defined in the Exclusive TTR License) as set forth in that certain Exclusive License Agreement entered into by and between the Parties as of the Execution Date (the &#8220;</font>Exclusive TTR License<font style="font-weight:normal;">&#8221;);</font></p>
<p style="Background-color:#auto;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: n